Business Context and Reporting Period
This Form 6-K is filed by pSivida Limited, a foreign issuer, for the month of February 2006. The report was signed on February 21, 2006, by Aaron Finlay, Chief Financial Officer and Company Secretary. The registrant files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of specific clinical trial results rather than a financial statement.
Material Changes
The filing highlights two significant developments regarding clinical trials:
- Positive long-term trial results for Uveitis.
- Updates regarding a Diabetic Macular Edema trial involving Retisert.
Guidance, Outlook, and Risks
The filing does not contain explicit financial guidance, management commentary on future outlook, or a discussion of risks and contingencies. The primary focus is the dissemination of the positive clinical data referenced in the exhibits.
Key Facts for Investor Verification
- Verify the specific statistical outcomes and duration of the positive Uveitis long-term trial results.
- Confirm the current status and design of the Diabetic Macular Edema trial with Retisert.
- Review subsequent filings for any financial impact resulting from these clinical milestones.